Market closedNon-fractional
bluebird bio/BLUE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About bluebird bio
Ticker
BLUE
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Somerville, United States
Employees
323
Website
www.bluebirdbio.com
bluebird bio Metrics
BasicAdvanced
$178M
Market cap
-
P/E ratio
-$0.90
EPS
0.86
Beta
-
Dividend rate
Price and volume
Market cap
$178M
Beta
0.86
Financial strength
Current ratio
1.554
Quick ratio
1.241
Long term debt to equity
104.263
Total debt to equity
136.475
Management effectiveness
Return on assets (TTM)
-15.01%
Return on equity (TTM)
-47.81%
Valuation
Price to revenue (TTM)
4.314
Price to book
0.44
Price to tangible book (TTM)
0.47
Price to free cash flow (TTM)
-0.327
Growth
Revenue change (TTM)
322.68%
Earnings per share change (TTM)
-85.08%
3-year revenue growth
-55.71%
3-year earnings per share growth
-56.36%
What the Analysts think about bluebird bio
Analyst Ratings
Majority rating from 13 analysts.
bluebird bio Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$12M
80.88%
Net income
-$72M
-1.65%
Profit margin
-582.92%
-45.63%
bluebird bio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
$0.38
$0.21
-$0.67
-$0.66
-
Expected
-$0.44
-$0.37
-$0.72
-$0.67
-$0.65
Surprise
-187.16%
-156.76%
-6.37%
-2.20%
-
bluebird bio News
AllArticlesVideos
![BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm](https://cdn.snapi.dev/images/v1/u/m/press20-2501198.jpg)
BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·1 week ago
![2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner](https://cdn.snapi.dev/images/v1/j/5/press11-2458223.jpg)
2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner
PRNewsWire·1 month ago
![Bluebird bio appoints new CFO to oversee financial restatements](https://cdn.snapi.dev/images/v1/y/j/biotech6-2451577.jpg)
Bluebird bio appoints new CFO to oversee financial restatements
Reuters·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for bluebird bio stock?
bluebird bio (BLUE) has a market cap of $178M as of July 06, 2024.
What is the P/E ratio for bluebird bio stock?
The price to earnings (P/E) ratio for bluebird bio (BLUE) stock is 0 as of July 06, 2024.
Does bluebird bio stock pay dividends?
No, bluebird bio (BLUE) stock does not pay dividends to its shareholders as of July 06, 2024.
When is the next bluebird bio dividend payment date?
bluebird bio (BLUE) stock does not pay dividends to its shareholders.
What is the beta indicator for bluebird bio?
bluebird bio (BLUE) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
![Buy or sell bluebird bio stock](/_next/image?url=%2Fresources%2Fimages%2Fpromo_phone.png&w=256&q=75)
Buy or sell bluebird bio stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.